Three years ago, Eli Lilly ( LLY 2.40%) and Novo Nordisk ( NVO +1.87%) had about the same market value. Given how well both ...

And it's not too late to get in on the action.

CrossBride Bio is developing a dual-payload cancer drug expected to begin human trials in 2026. ・The U.S. Food and Drug ...

On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the news they were eagerly awaiting: the approval of the company's GLP-1 pill, Foundayo. While the company isn't the first out of the ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early ...

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill - At the heart of the request is ...

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s ...

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo (orforglipron) to eligible ...

Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% ...

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle ...